Literature DB >> 24917609

Diagnostic value of dual time-point 18 F-FDG PET/CT versus single time-point imaging for detection of mediastinal nodal metastasis in non-small cell lung cancer patients: a meta-analysis.

Guohua Shen1, Shuang Hu1, Houfu Deng1, Zhiyun Jia2.   

Abstract

BACKGROUND: Lymph node staging in non-small cell lung cancer (NSCLC) is challenging and important for determining treatment policy. Conflicting results have been presented to date.
PURPOSE: To evaluate the diagnostic performance of dual time-point (DTP) 18 F-FDG PET/CT compared with single time-point (STP) imaging for detecting mediastinal nodal metastases in patients with NSCLC.
MATERIAL AND METHODS: The PubMed, EMBASE, EBSCO, and Web of Knowledge databases were searched for relevant articles. The pooled sensitivity, specificity, diagnostic odds ratio (DOR), positive likelihood ratio (PLR), and negative likelihood ratio (NLR) were calculated using Meta-Disc software. Summary receiver-operating characteristic (SROC) curves were also constructed. The potential for between-study heterogeneity was explored using subgroup analyses.
RESULTS: A total of eight studies involving 654 patients fulfilled the inclusion criteria. On a per-patient analysis, the pooled sensitivity and specificity with a 95% confidence interval (CI) for DTP PET/CT were 0.85 (0.78-0.91), 0.75 (0.68-0.82), and for STP imaging, they were 0.79 (0.70-0.85), 0.73 (0.65-0.79), respectively. On a per-lesion basis, the corresponding values for DTP imaging were 0.84 (0.81-0.86), 0.89 (0.87-0.91), and for STP imaging, they were 0.84 (0.80-0.86), 0.83 (0.81-0.85), respectively.
CONCLUSION: DTP PET/CT performed better than STP imaging in evaluating the lymph node status of NSCLC patients and had the potential to be broadly applied in clinical practice. However, due to the small sample size and large heterogeneity, current evidence does not justify the implementation of DTP imaging in routine PET protocols for mediastinal lymph node staging of NSCLC. © The Foundation Acta Radiologica 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  18 F-FDG PET/CT; Dual time-point; lymph node staging; meta-analysis; non-small cell lung cancer

Mesh:

Substances:

Year:  2014        PMID: 24917609     DOI: 10.1177/0284185114535210

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  4 in total

1.  Dual-time point 18F-FDG PET/CT for the staging of oesophageal cancer: the best diagnostic performance by retention index for N-staging in non-calcified lymph nodes.

Authors:  Sohyun Park; Jin Chul Paeng; Chang Hyun Kang; Gi Jeong Cheon; Keon Wook Kang; June-Key Chung; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-03       Impact factor: 9.236

2.  Dual time point imaging for F18-FDG-PET/CT does not improve the accuracy of nodal staging in non-small cell lung cancer patients.

Authors:  Julian M M Rogasch; Ingo G Steffen; Sandra Riedel; Ivayla Apostolova; Heinz Wertzel; H Jost Achenbach; Ferdinand L G A Steinkrüger; Thomas Kalinski; Meinald Schultz; Jens Schreiber; Holger Amthauer; Christian Furth
Journal:  Eur Radiol       Date:  2015-11-11       Impact factor: 5.315

3.  Anisakiasis mimics cancer recurrence: two cases of extragastrointestinal anisakiasis suspected to be recurrence of gynecological cancer on PET-CT and molecular biological investigation.

Authors:  Yuya Nogami; Yoko Fujii-Nishimura; Kouji Banno; Atsushi Suzuki; Nobuyuki Susumu; Taizo Hibi; Koji Murakami; Taketo Yamada; Hiromu Sugiyama; Yasuyuki Morishima; Daisuke Aoki
Journal:  BMC Med Imaging       Date:  2016-04-26       Impact factor: 1.930

4.  Prognostic value of the standardized uptake value maximum change calculated by dual-time-point (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with advanced non-small-cell lung cancer.

Authors:  Feng Jin; Hui Zhu; Zheng Fu; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-05-19       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.